News

Key market players identified include ADM, Cargill Inc., Chevron Renewable Energy Group, Green Plains Inc., POET LLC, and Neste. The analysis segments the market by fuel type, end‑use industry, and region, and provides competitive intelligence on each company’s market share based on product offerings and biofuel revenues.

Full article

The report highlights supply‑chain complexity and feedstock availability as key challenges, emphasising that securing competitive‑cost feedstock is critical to site selection decisions. Advances in technology and tightening economic pressures are shaping the competitive landscape.

Full article

Global biofuels sales are projected to rise from $150.9 billion in 2025 to $194.7 billion by the end of 2030, a compound annual growth rate of 5.2 % from 2025 through 2030. The surge is driven by mounting demand in transportation, aviation, and marine sectors as part of worldwide decarbonisation initiatives. Ethanol and renewable diesel are expecte...

Full article

To counter the revenue slide, Novo launched an oral Wegovy pill that has attracted more than 170 k U.S. patients and announced a share‑buyback up to DKK 15 bn. Management changes—including the appointment of Jamey Millar to lead the U.S. business and restructuring of U.S. product‑strategy teams—support a transformation agenda that stresses cost dis...

Full article

On 12 Apr 2026, shares plunged by as much as 20 % in early trading after the company warned that 2026 sales and earnings could fall 5 – 13 % and that current‑year revenue could decline up to 13 %. The downtick coincided with a broader sell‑off in the obesity‑drug sector triggered by rivals Eli Lilly’s Mounjaro, which reported a 110 % rise in sales...

Full article

Novo’s shareholder return since 2019 exceeds DKK 300 bn, with a proposed final dividend of DKK 11.70 for 2025. The company’s gross margin fell to 81 % from 84.7 % in 2024 due to amortisation and restructuring costs, and operating profit fell 1 % in DKK. Overall, the company treats nearly 46 m patients worldwide and aims to preserve its leadership i...

Full article

Despite the headwinds, Novo maintains growth in its GLP‑1 pipeline. Early‑stage candidates include CagriSema for type‑2 diabetes and Senagametide (formerly amycretin). The company also advanced an oral GLP‑1RA pill, expected to enter the market in the second half of 2025, with the pill version of Wegovy projected to drive significant weight‑loss (1...

Full article

The guidance triggered a sharp market reaction. Shares fell 18 % in Copenhagen and up to 20 % on 4 Feb 2026 following the 2026 outlook, wiping approximately $32 bn–$47 bn of market value. The decline was driven by expectations of a 13 % drop in 2026 sales and profits, the first negative growth outlook in years, and intensified competition from gene...

Full article

During its Q4 earnings call on 4 Feb 2026, Novo highlighted a forecasted decline of 5 %–13 % in sales and operating profit at constant exchange rates for 2026. The outlook cites lower realized prices, U.S. pricing effects under President Trump’s MFN policy and the IRA, mix and cash‑pay shifts, and the loss of semaglutide exclusivity in Brazil, Cana...

Full article

Novo Nordisk AS reported 10 % sales growth and 6 % operating‑profit growth for 2025 at constant exchange rates. Obesity‑care revenue climbed from DKK 6 bn in 2019 to DKK 82 bn in 2025, a 31 % annual growth rate, while GLP‑1 sales expanded over 30 % in 2025. Wegovy generated DKK 28 bn in international sales, up 134 % versus the prior year, and Ozemp...

Full article